APA (7th ed.) Citation

MJ, H., JM, M., BC, P., JA, R., J, M., AD, S., . . . JS, R. (2025). Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: An open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled study. The Lancet. Microbe, 6(4), 101000. https://doi.org/10.1016/j.lanmic.2024.101000

Chicago Style (17th ed.) Citation

MJ, Hamer, et al. "Safety and Immunogenicity of an Adjuvanted Chikungunya Virus Virus-like Particle (CHIKV VLP) Vaccine in Previous Recipients of Other Alphavirus Vaccines Versus Alphavirus Vaccine-naive Controls: An Open-label, Parallel-group, Age-matched, Sex-matched, Phase 2 randomised Controlled study." The Lancet. Microbe 6, no. 4 (2025): 101000. https://doi.org/10.1016/j.lanmic.2024.101000.

MLA (9th ed.) Citation

MJ, Hamer, et al. "Safety and Immunogenicity of an Adjuvanted Chikungunya Virus Virus-like Particle (CHIKV VLP) Vaccine in Previous Recipients of Other Alphavirus Vaccines Versus Alphavirus Vaccine-naive Controls: An Open-label, Parallel-group, Age-matched, Sex-matched, Phase 2 randomised Controlled study." The Lancet. Microbe, vol. 6, no. 4, 2025, p. 101000, https://doi.org/10.1016/j.lanmic.2024.101000.